Pharmacotherapeutic Options for Visceral Leishmaniasis—Current Scenario
Visceral leishmaniasis (VL) or Kala-azar is a protozoal disease, which was previously regarded as one of the most neglected tropical diseases. Management of this disease is quite difficult, because it is said to affect the poorest of the poor. Previously Sodium Stibogluconate (SSG) was regarded as t...
Main Authors: | Krishna Pandey MD, Prabhat Kumar Sinha, Vidyanand Ravi Das, Sanjiva Bimal, Shubhankar K. Singh, Pradeep Das |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2009-01-01
|
Series: | Clinical Medicine Insights: Pathology |
Online Access: | https://doi.org/10.4137/CPath.S821 |
Similar Items
-
Tuberous sclerosis with visceral leishmaniasis: a case report
by: Pandey Krishna, et al.
Published: (2009-09-01) -
Early diagnostic marker for the conversion of asymptomatic to symptomatic visceral leishmaniasis
by: Roshan Kamal Topno, et al.
Published: (2019-07-01) -
One More Death from Visceral Leishmaniasis Has Gone by Unnoticed. What Can Be Done?
by: Greg Matlashewski, et al.
Published: (2013-06-01) -
Identification of Leishmania donovani antigen in circulating immune complexes of visceral leishmaniasis subjects for diagnosis.
by: Fauzia Jamal, et al.
Published: (2017-01-01) -
Elevated Serum ADA Activity as a Marker for Diagnosis and Prognosis of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis in Indian Patients.
by: Vijayamahantesh, et al.
Published: (2016-01-01)